Peptron, Inc.
KOSDAQ 087010.KQ
Peptron, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 20,581,276
Peptron, Inc. Shares (Diluted, Weighted) is 20,581,276 for the year ending December 31, 2023, a -0.22% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
-
Peptron, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 20,626,853, a 0.00% change year over year.
-
Peptron, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 20,626,853, a 34.20% change year over year.
-
Peptron, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 15,369,946, a -4.74% change year over year.
-
Peptron, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 16,134,270, a -5.13% change year over year.
Key data
| Date | Shares (Diluted, Weighted) | Revenue | Cost of Revenue | Gross Profit |
|---|
Market news
Loading...
Don’t Miss A Beat
KOSDAQ: 087010.KQ
| CEO | Mr. Ho-Il Choi |
| IPO Date | July 22, 2015 |
| Location | South Korea |
| Headquarters | 37-24, Yuseong-daero 1628 beon-gil |
| Employees | 94 |
| Sector | Healthcare |
| Industries | |
Description
Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
Key trends
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email